June 2020
Volume 61, Issue 7
ARVO Annual Meeting Abstract  |   June 2020
Disease Activity Assessments with Brolucizumab vs Aflibercept in Patients with nAMD in HAWK and HARRIER
Author Affiliations & Notes
  • Rishi P Singh
    Ophthalmology i-32, Cole Eye Institute, Cleveland, Ohio, United States
  • Robin Hamilton
    Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
  • Jeffrey S Heier
    Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
  • Carl Regillo
    Wills Eye Hospital, Philadelphia, Pennsylvania, United States
  • Mark C Gillies
    Macula Research Group, Sydney Eye Hospital, Sydney, New South Wales, Australia
  • Georges Weissgerber
    Novartis Pharma AG, Basel, Switzerland
  • Jahangir Alam
    Novartis Pharma AG, Basel, Switzerland
  • Pravin U Dugel
    Retinal Consultants of Arizona,, Phoenix, Arizona, United States
  • Footnotes
    Commercial Relationships   Rishi Singh, Alcon (C), Apellis (F), Bausch + Lomb (C), Genentech (C), Novartis (C), Optos (C), Regeneron/Bayer (C), Zeiss (C); Robin Hamilton, Allergan (C), Allergan (R), Bayer Healthcare (C), Bayer Healthcare (F), Bayer Healthcare (R), Novartis Pharmaceuticals (C), Novartis Pharmaceuticals (F), Novartis PharmaceuticalsNovartis Pharmaceuticals (R), Roche (C), Roche (F), Roche (R); Jeffrey Heier, 4D Molecular Technologies (F), Acucela (F), Adverum (F), Aerie (F), Aerpio (F), Allegro (F), Apellis (F), Asclepix (F), Astellas (F), Bayer (F), BVI (F), Coda Therapeutix (F), Corcept (F), Daiichi Sankyo (F), Genentech/Roche (F), Genzyme (F), Heidelberg (F), Hemera (F), Janssen R&D (F), Kanghong (F), Kodiak (F), Neurotech (F), Notal Vision (F), Novartis (F), Ocular Therapeutix (F); Carl Regillo, Aerpio (F), Allegro (C), Allergan (C), Allergan (F), Astellis (F), Chengdu Kanghong Biotechnology (F), Chengdu Kanghong Biotechnology (C), Genentech (C), Genentech (F), Iconic (C), Iconic (F), Kodiak,Merck (C), Notal Vision (C), Novartis (C), Novartis (F), Ophthotech (F), Opthea (F), Regeneron (F), Santen (C), Shire (C), Teva (C); Mark Gillies, Allergan (C), Allergan (F), Bayer (C), Bayer (F), Novartis (C), Novartis (F), Roche (C), Roche (F); Georges Weissgerber, Novartis (E); Jahangir Alam, Novartis (E); Pravin Dugel, Alcon Pharmaceutical (C), Alcon Surgical (C), Alcon Surgical (RACII) (C), Allergan (C), Annidis (C), Avalanche (C), Bausch + Lomb Pharma (C), CDR-Life Inc (C), Clearside Biomedical (C), Digisight (C), Genentech (C), Graybug Vision (C), Irenix (C), Lutronic (C), Lux BioScience (C), NeoVista (C), Novartis (C), Omeros (C), Ophthotech (C), Opthea (C), ORA (C), Orbis International (C), Santen Inc. (C), Shire Human Genetics (C), TrueVision (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 1158. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rishi P Singh, Robin Hamilton, Jeffrey S Heier, Carl Regillo, Mark C Gillies, Georges Weissgerber, Jahangir Alam, Pravin U Dugel; Disease Activity Assessments with Brolucizumab vs Aflibercept in Patients with nAMD in HAWK and HARRIER. Invest. Ophthalmol. Vis. Sci. 2020;61(7):1158.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : To compare the presence of disease activity (DA) over 96 weeks in HAWK and HARRIER, two Phase III, prospective trials that assessed the efficacy and safety of brolucizumab (Bro) vs aflibercept (Afl) in treatment-naïve patients with nAMD.

Methods : Patients were randomized 1:1:1 to Bro 3mg (n=358), 6mg (n=360) or Afl 2mg (n=360) in HAWK, or 1:1 to Bro 6mg (n=370) or Afl 2mg (n=369) in HARRIER. After 3 monthly loading doses, Bro patients received 12-week (q12w) dosing unless DA was present (as identified by masked investigator) at any predefined disease activity assessment (DAA) visit and resulted in permanent 8-week (q8w) dosing; Afl was dosed at fixed q8w. DAA occurred at Weeks 16, 20, 32, 44, 56, 68, 80, 92 with additional DAA at Weeks 28, 40, 52, 64, 76, and 88 in HARRIER only. All patients continued with planned DAA until the study end based on DAA guidance described in the study protocol, where ultimately the masked investigator took the final treatment decision based on their clinical judgment. The first DAA at Week 16 allowed for head-to-head comparison between treatment arms for q8w dosing need.

Results : At Week 16, DA presence and therefore q8w dosing need was statistically significantly lower with Bro vs Afl in both HAWK (Bro 3mg=28.1%; Bro 6mg=24.0% vs Afl=34.5%; p<0.03 for both) and HARRIER (Bro 6mg=22.7% vs Afl=32.2%; p=0.002). DA presence was higher with Afl vs Bro (HAWK/HARRIER: Afl=22.2% / 19.6% vs Bro 3mg=14.9% / 0%; Bro 6mg=13.6% / 15.7%) across all DAA from Week 16 through 96. Further, qualitative analysis of all DAA in HAWK/HARRIER showed that across all treatment arms (given the masked investigator assessment), in 71.4% / 67.7% of the cases anatomical signs of DA were present either alone (35.8% / 41.9%) or in combination with function (35.6% / 25.8%).

Conclusions : Together, the functional and anatomical DA evaluations in HAWK and HARRIER indicate that nAMD patients treated with Bro 6mg q12w/q8w have lower risk of DA occurrence than Afl and thereby better disease control.

This is a 2020 ARVO Annual Meeting abstract.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.